ArriVent BioPharma prices $75M public offering of common stock and pre-funded warrants

ArriVent BioPharma, Inc.

Raised ~$75M gross; priced 2,482,692 shares at $19.50 and 1,363,469 pre-funded warrants at $19.4999.
Underwriters have 30-day option to purchase up to 576,923 additional shares on same terms.
Proceeds to fund firmonertinib and other pipeline programs, plus working capital.
Expected close July 3, 2025; joint bookrunners: Goldman Sachs, Citigroup, Guggenheim Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.